InflaRx is a privately owned drug biotech company focused on developping new therapeutic approaches to prevent and treat sepsis, one of the leading cause of deaths in hospitals. Located in the sepsis hub of Jena (Germany), InflaRx is concentrated on new targets within the complement field and has already brought its leading development program in an advanced pre-clinical stage.
affentranger associates is involved in the strategic development of InflaRx and is represented at the Board of Directors.
For more information, please visit www.InflaRx.com.
related news
| 18 Jan 2012 | InflaRx: InflaRx announces successful conduct of its clinical phase I trial with IFX-1 |
| 18 May 2009 | InflaRx: company profile published in BioCentury |
| 20 Mar 2009 | InflaRx: closes funding to move its complement antibody program into clinical trials for sepsis treatment |
| 18 Mar 2008 | InflaRx raises financing to develop a new therapeutic approach against sepsis |
